The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC): A report of 2,781 cases in a Chinese population.
Bethesda system
FNA
NIFTP
cytopathology
thyroid
Journal
Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
ISSN: 1000-9604
Titre abrégé: Chin J Cancer Res
Pays: China
ID NLM: 9315242
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
entrez:
16
5
2020
pubmed:
16
5
2020
medline:
16
5
2020
Statut:
ppublish
Résumé
To evaluate the diagnostic utility of The Bethesda System for Reporting Thyroid Cytology (TBSRTC) at Peking University Cancer Hospital, the incidence of noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP), and the impact of reclassification on cytopathological outcomes. We performed a retrospective study of thyroid fine-needle aspiration (FNA) cases between April 2014 and March 2019. The FNA results were classified according to TBSRTC. Post-surgery histological findings were followed up. A total of 2,781 thyroid FNAs were performed. The incidences of the 6 diagnostic categories (DCs I-VI) were 14.8%, 17.1%, 15.8%, 2.3%, 11.6% and 38.5%, respectively. A total of 1,122 patients (40.3%) had corresponding histological results. NIFTP accounted for 0.4% of papillary thyroid carcinoma (PTC) cases, and there was no significant difference in the risk of malignancy (ROM) for each TBSRTC DC between "NIFTP=carcinoma (Ca)" and "NIFTP≠Ca". When "NIFTP=Ca", the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of TBSRTC were 98.0%, 84.0%, 99.4%, 58.3%, and 97.5%, respectively. When "NIFTP≠Ca", the sensitivity, specificity, PPV, NPV and accuracy of the TBSRTC were 98.1%, 81.5%, 99.3%, 61.1%, and 97.5%, respectively. TBSRTC is effective in the preoperative diagnosis of thyroid nodules in Peking University Cancer Hospital. The impact of the reclassification of NIFTP on cytopathological outcomes is limited because of its low incidence, and the revised ROMs are not suitable for Asian patients.
Identifiants
pubmed: 32410792
doi: 10.21147/j.issn.1000-9604.2020.02.02
pii: cjcr-32-2-140
pmc: PMC7219100
doi:
Types de publication
Journal Article
Langues
eng
Pagination
140-148Informations de copyright
Copyright © 2020 Chinese Journal of Cancer Research. All rights reserved.
Références
Thyroid. 2017 Jul;27(7):983-984
pubmed: 28486057
Am J Clin Pathol. 2015 Dec;144(6):850-7
pubmed: 26572991
Endocrinol Metab Clin North Am. 2017 Sep;46(3):691-711
pubmed: 28760234
Thyroid. 2018 May;28(5):556-565
pubmed: 29591914
J Pathol Transl Med. 2018 May;52(3):171-178
pubmed: 29614546
Pathology. 2018 Jun;50(4):411-417
pubmed: 29631726
Cancer Cytopathol. 2012 Apr 25;120(2):111-6
pubmed: 21919213
Otolaryngol Head Neck Surg. 2008 Jul;139(1):27-31
pubmed: 18585557
J Thyroid Res. 2013;2013:250347
pubmed: 23634318
Ann Surg Oncol. 2012 Jan;19(1):45-51
pubmed: 21633868
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Otolaryngol Clin North Am. 2010 Apr;43(2):257-71, vii-viii
pubmed: 20510713
Ann Med Surg (Lond). 2016 Aug 02;10:92-102
pubmed: 27594994
Cancer. 2000 Dec 25;90(6):325-9
pubmed: 11156514
Hum Pathol. 2016 Aug;54:134-42
pubmed: 27085556
Clin Endocrinol (Oxf). 2017 Mar;86(3):444-450
pubmed: 27761926
Endocr J. 2017 Dec 28;64(12):1149-1155
pubmed: 28904306
Thyroid. 1998 Jan;8(1):15-21
pubmed: 9492148
Expert Rev Endocrinol Metab. 2014 Mar;9(2):97-110
pubmed: 30743753
Cancer Cytopathol. 2017 Jun;125(6):378-388
pubmed: 28296267
Endocr Pathol. 2018 Sep;29(3):276-288
pubmed: 29476382
Endocr Pract. 2004 May-Jun;10(3):242-245
pubmed: 15310533
Cancer Cytopathol. 2016 Mar;124(3):181-7
pubmed: 26457584
Thyroid. 2017 Nov;27(11):1341-1346
pubmed: 29091573
Am J Clin Pathol. 2006 Jun;125(6):873-82
pubmed: 16690487
Acta Cytol. 2012;56(4):333-9
pubmed: 22846422
Clin Diabetes Endocrinol. 2016 Oct 3;2:17
pubmed: 28702251
Am J Clin Pathol. 2016 Sep;146(3):373-7
pubmed: 27543982